Compare Match Group Inc (MTCH) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Summit Therapeutics Inc — how do they compare? Match Group Inc trades at $41.46 (market cap $9.45B), while Summit Therapeutics Inc trades at $17.55 (market cap $13.79B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Match Group Inc pays a 1.94% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTCH | SMMT | |
|---|---|---|
Market Cap | $9.45B | $13.79B |
Sector | Media | Health |
52-Week High | $42.44 | $26.38 |
52-Week Low | $28.90 | $12.43 |
Enterprise Value | $12.41B | $13.11B |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near the analyst low target of $41.00. The stock shows a bullish technical trend with recent earnings beating expectations in Q2 2026. Fundamentals are solid with a P/E of 14.59, net income margin of 20.17%, and strong cash flow growth. Recent news highlights AI-driven product innovations at Tinder and institutional buying interest.
Outlook is positive with a consensus price target of $42.50, offering modest upside. Key opportunities include AI integration and user growth, while risks involve high debt levels and competitive pressures in the dating app market. The stock presents a balanced risk-reward profile for growth-oriented investors.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
